Pfizer Inc. (FRA:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 139.54B +11.2% |
| Revenue (ttm) | 55.85B -0.2% |
| Net Income | 3.80B -59.7% |
| EPS | 0.67 -59.9% |
| Shares Out | n/a |
| PE Ratio | 36.72 |
| Forward PE | 9.95 |
| Dividend | 1.48 (6.08%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 24,173 |
| Open | 24.45 |
| Previous Close | 24.39 |
| Day's Range | 24.30 - 24.47 |
| 52-Week Range | 20.13 - 24.86 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Pfizer Stock (PFE) Is a Buy despite Declining Revenue
Pfizer ($PFE) stock is a Buy despite declining revenue, in my view. Shares of the drugmaker have been modestly ahead of the S&P 500 (SPX) in 2026, helped by an…
Pfizer (PFE) Stock Rallies 4% Thanks to Merck (MRK) and Moderna (MRNA)’s Cancer Trial Update
Pfizer stock was up 3.74% thanks to a clinical trial update from Merck and Moderna that showed the potential of an MRNA vaccine as a cancer treatment.
Pfizer, Valneva announce EMA validation for PF-07307405 MAA
Pfizer (PFE) and Valneva (VALN) announced that the European Medicines Agency, or EMA, has validated the marketing authorization application, or MAA, for PF-07307405, the companies’ 6-valent outer surf...
Pfizer (PFE) CEO Buys $1 Million of Company Stock
The pharma giant’s earnings beat Wall Street forecasts.
Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase
Three Pfizer insiders executed transactions directly on the heels of the drugmaker's second-quarter earnings report.
Closed Pfizer biopharma facility in Everett gets a new lease on life
A biomanufacturing facility in Everett that Pfizer decided to shut down before it opened is getting a new lease on life, with a new owner and a 21-year lease to an unnamed global biopharmaceutical com...
Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money
Pharmaceutical company Pfizer has agreed to a $44 million class action settlement over its oral prescription medication Chantix. Approved by the FDA in May 2006 as a smoking-cessation aid, the drug wa...
Valneva Stock (VALN) Soars Over 20% On Lyme Disease Vaccine Hopes
Shares in biotech Valneva ($VALN) soared over 20% in early trading today after it and partner Pfizer ($PFE) as it moved closer to bringing its Lyme disease vaccine to Europe.
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketin...
Pfizer price target lowered to $31 from $35 at Guggenheim
Guggenheim lowered the firm’s price target on Pfizer (PFE) to $31 from $35 and keeps a Buy rating on the shares.
Pfizer Earnings Call Transcript: Q2 2026
Q2 2026 revenue and adjusted EPS exceeded expectations, driven by strong growth in launched and acquired products, especially in oncology and migraine. Full-year revenue guidance was raised, with continued cost savings initiatives and a reaffirmed dividend commitment.
Pfizer Earnings release: Q2 2026
Pfizer released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Pfizer Slides: Q2 2026
Pfizer has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Pfizer Quarterly report: Q2 2026
Pfizer has published its Q2 2026 quarterly earnings report on August 4, 2026.
Pfizer Post Loss on Higher Revenue
Pfizer swung to a second-quarter loss but posted higher revenue, as market growth in its oncology business offset some declines in its Covid-19 products.
Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
Pfizer reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing the stronger-than-expected performance of non-Covid products. The company is now expe...
Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings
Pfizer beats earnings forecasts for the second quarter, while BioNTech's results miss expectations due to weak Covid vaccine demand.
Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
Pfizer beat Wall Street estimates for second-quarter profit on Tuesday, driven by strong demand for its blood thinner, Eliquis.
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffi...
Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials
Pfizer said on Thursday its oral drug helped restore skin color in patients with a common form of vitiligo in two late-stage trials, paving the way for regulatory submissions seeking approval in the...
Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from two Phase 3 trials evaluating the efficacy and safety of LITFULO once daily in patients with both activ...
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authori...
Pfizer's prostate cancer drug combination gets US FDA priority review
Pfizer said on Wednesday the U.S. Food and Drug Administration has granted priority review to its application seeking expanded approval for its prostate cancer treatment combination.
FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA...
Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later
President Donald Trump said on Tuesday all generic drugs being brought into the U.S. will continue having a tariff of 0% for two years starting from August 1, after which the tariff rate wi...